Ascletis Pharma Inc. (ASCLF)
USD 0.24
(0.0%)
USD 0.24
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 148.94 Million CNY | 27.13% |
| 2022 | 117.15 Million CNY | 16.13% |
| 2021 | 100.88 Million CNY | 18.1% |
| 2020 | 85.42 Million CNY | -16.39% |
| 2019 | 102.17 Million CNY | 1.98% |
| 2018 | 100.19 Million CNY | -17.49% |
| 2017 | 121.42 Million CNY | -4.53% |
| 2016 | 127.18 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 95.79 Million CNY | -35.69% |
| 2024 Q2 | 95.79 Million CNY | 0.0% |
| 2023 Q2 | 90.78 Million CNY | 0.0% |
| 2023 Q1 | 90.78 Million CNY | -22.51% |
| 2023 FY | 148.94 Million CNY | 27.13% |
| 2023 Q4 | 148.94 Million CNY | 0.0% |
| 2023 Q3 | 148.94 Million CNY | 64.06% |
| 2022 Q2 | 108.89 Million CNY | 0.0% |
| 2022 FY | 117.15 Million CNY | 16.13% |
| 2022 Q1 | 108.89 Million CNY | 7.94% |
| 2022 Q4 | 117.15 Million CNY | 0.0% |
| 2022 Q3 | 117.15 Million CNY | 7.59% |
| 2021 FY | 100.88 Million CNY | 18.1% |
| 2021 Q3 | 100.88 Million CNY | 28.34% |
| 2021 Q4 | 100.88 Million CNY | 0.0% |
| 2021 Q1 | 78.61 Million CNY | -7.97% |
| 2021 Q2 | 78.61 Million CNY | 0.0% |
| 2020 Q2 | 81.65 Million CNY | 0.0% |
| 2020 Q3 | 85.42 Million CNY | 4.62% |
| 2020 Q4 | 85.42 Million CNY | 0.0% |
| 2020 FY | 85.42 Million CNY | -16.39% |
| 2020 Q1 | 81.65 Million CNY | -20.08% |
| 2019 Q2 | 82.64 Million CNY | 0.0% |
| 2019 FY | 102.17 Million CNY | 1.98% |
| 2019 Q4 | 102.17 Million CNY | 0.0% |
| 2019 Q3 | 102.17 Million CNY | 23.62% |
| 2019 Q1 | 82.64 Million CNY | -11.52% |
| 2018 Q1 | 89.96 Million CNY | -9.33% |
| 2018 FY | 100.19 Million CNY | -17.49% |
| 2018 Q4 | 93.4 Million CNY | 0.0% |
| 2018 Q3 | 93.4 Million CNY | -19.64% |
| 2018 Q2 | 116.23 Million CNY | 29.19% |
| 2017 FY | 121.42 Million CNY | -4.53% |
| 2017 Q1 | - CNY | 0.0% |
| 2017 Q3 | 99.22 Million CNY | 0.0% |
| 2017 Q4 | 99.22 Million CNY | 0.0% |
| 2016 FY | 127.18 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -179.417% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -1454.401% |
| SQZ Biotechnologies Company | 50.03 Million USD | -197.654% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -105.521% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -152.386% |
| Mesoblast Limited | 188.44 Million USD | 20.962% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -3767.219% |
| Genus plc | 485 Million USD | 69.29% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -2449.25% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -5819.061% |
| Marizyme, Inc. | 26.67 Million USD | -458.347% |
| ContraFect Corporation | 32.53 Million USD | -357.849% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -3819.553% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -7417.408% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -3791.241% |
| Intellipharmaceutics International Inc. | 12 Million USD | -1140.286% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -1164.566% |
| MultiCell Technologies, Inc. | 1617.67 USD | -9207154.879% |
| Accustem Sciences Inc. | 1.07 Million USD | -13700.743% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -92.391% |
| EV Biologics, Inc. | 2.11 Million USD | -6941.992% |
| Q BioMed Inc. | 8.13 Million USD | -1731.355% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -79.59% |
| Neon Bloom, Inc. | 1.22 Million USD | -12046.585% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -2794.325% |
| Biomind Labs Inc. | 1.49 Million USD | -9838.73% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 38.976% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -709.323% |
| Skye Bioscience, Inc. | 14.07 Million USD | -958.418% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -7309.62% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -104719.311% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -1473.465% |
| IMV Inc. | 37.93 Million USD | -292.65% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -73958.255% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -2492.197% |
| GB Sciences, Inc. | 5.41 Million USD | -2649.265% |
| Alpha Cognition Inc. | 7.16 Million USD | -1978.823% |
| HST Global, Inc. | 593.59 Thousand USD | -24991.772% |
| CSL Limited | 18.62 Billion USD | 99.2% |
| Halberd Corporation | 728.71 Thousand USD | -20339.017% |
| Enzolytics Inc. | 365.26 Million USD | 59.224% |
| Resverlogix Corp. | 67.39 Million USD | -120.997% |
| Affymax, Inc. | 8.87 Million USD | -1578.988% |
| SYBLEU INC | 681.41 Thousand USD | -21757.963% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -17658.116% |
| argenx SE | 444.95 Million USD | 66.526% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -98.803% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -8589.79% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -1151.296% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -3963.747% |
| AVAX Technologies, Inc. | 3.99 Million USD | -3629.407% |
| Zenith Capital Corp. | 27.56 Thousand USD | -540155.359% |
| Genscript Biotech Corporation | 1.32 Billion USD | 88.766% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -62309.597% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -3888.505% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -21776.551% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -25.455% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -1547.2% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -222438.81% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -10287.548% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -196.321% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -5392.726% |
| BioStem Technologies, Inc. | 15.9 Million USD | -836.474% |
| ONE Bio Corp. | 27.49 Million USD | -441.693% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -31951.5% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -542833.693% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -11728.449% |
| Agentix Corp. | 2.51 Million USD | -5832.672% |
| LadRx Corporation | 2.2 Million USD | -6668.512% |
| Cell Source, Inc. | 15.8 Million USD | -842.277% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -333135.636% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2629.085% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2629.085% |
| NovAccess Global Inc. | 7.86 Million USD | -1794.773% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -501.887% |
| Itoco Inc. | 1.65 Million USD | -8909.643% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -7159.97% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -2362.275% |
| Kadimastem Ltd | 3.5 Million USD | -4149.605% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -35230.718% |
| CytoDyn Inc. | 127.89 Million USD | -16.458% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -356231.491% |
| Mobile Lads Corp. | 1.31 Million USD | -11239.424% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -9408.758% |
| Qrons Inc. | 1.48 Million USD | -9904.816% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -1248.475% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -18315.443% |
| Rebus Holdings, Inc. | 5.24 Million USD | -2741.339% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -2340.926% |
| International Stem Cell Corporation | 5.27 Million USD | -2722.494% |
| Bioxytran, Inc. | 3.24 Million USD | -4483.567% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -23700.073% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -3125.882% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -263.311% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -568.956% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -7253.804% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -2618.93% |
| Neutra Corp. | 973.52 Thousand USD | -15199.287% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -413.331% |
| PureTech Health plc | 125.58 Million USD | -18.601% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -3864.281% |
| IXICO plc | 1.9 Million USD | -7737.901% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -625.525% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -44.151% |
| CSL Limited | 18.62 Billion USD | 99.2% |
| Cellectis S.A. | 249.36 Million USD | 40.272% |